Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia

NCT ID: NCT02727361

Last Updated: 2019-02-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-01-31
• Study Completion Date: 2018-03-01

Brief Summary

Dystonia is defined as a syndrome of sustained muscle contractions resulting in repetitive movements and abnormal postures. DYT1 is the most common form of genetic dystonia, but the link between genomic mutations and phenotypic expression remains largely unknown. Furthermore, secondary forms of dystonia have highlighted the role of the basal ganglia, particularly the putamen in the pathophysiology of the disease. Experimental results in a genetic model of dystonia in rodents suggest that cholinergic inter-neurons (ACh-I) of the putamen play a critical role in the pathological process of plasticity in the cortico-striatal synapse. However, these results have not been demonstrated in humans.

Detailed Description

The purpose of this study is to demonstrate that the phenotype of dystonia is associated with the degree of striatal ACh-I alterations.

In this molecular imaging study, the investigators will directly test this hypothesis using a PET radiotracer of the vesicular acetylcholine transporter (VAT). Their goal is to explore the relationships between cholinergic dysfunction and clinical disease expression and the associated morphological and functional alterations. The experimental protocol will also include multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).

Conditions

Dystonia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

Cholinergic striatal imaging

Cholinergic striatal imaging (IRM and TEP) to compare the intensity of the binding of cholinergic tracer

Group Type: EXPERIMENTAL

PET (Positron Emission Tomography) imaging

Intervention Type: RADIATION

Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.

MRI : Magnetic Resonance Imaging

Intervention Type: OTHER

Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).

Interventions

PET (Positron Emission Tomography) imaging

Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.

Intervention Type: RADIATION

MRI : Magnetic Resonance Imaging

Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Man or woman 18 to 75 years, with health insurance European health insurance card (for resident patients in EU), insurance by bilateral social security agreement signed between his country and France (for resident patients outside the EU)
• Diagnosis of dystonia DYT1 confirmed by molecular biology (TORSINE- A gene mutation)
• Patient who stopped his anticholinergic treatment 48 hours before imaging

Exclusion Criteria

• Patients who underwent surgery for deep brain stimulation or under cholinergic treatment.
• Presence of a counter-indication for MRI
• Presence of a counter-indication for TEP Scan with [18F]-FEOBV
• Woman premenopausal without effective ongoing contraception (intrauterine device or combined hormonal)
• Patient who underwent a PET examination in the previous month
• Presence of any health problem preventing travel to the imaging service of the University Hospital
• Being under the legal guardianship of another person or being unable to provide consent to participate
• Pregnant or breastfeeding woman

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Hospital, Bordeaux

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

FERNANDEZ Philippe

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bordeaux

BURBAUD Pierre

Role: STUDY_CHAIR

University of Bordeaux

Locations

CHU de Bordeaux

Bordeaux, , France

Countries

France

Other Identifiers

CHUBX2014/20

Identifier Type: -

Identifier Source: org_study_id